Literature DB >> 30266766

Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats.

Jeremy Carlier1, Ariane Wohlfarth1, Bonita D Salmeron1, Karl B Scheidweiler1, Marilyn A Huestis1, Michael H Baumann2.   

Abstract

Novel synthetic cannabinoids are appearing in recreational drug markets worldwide. Pharmacological characterization of these new drugs is needed to inform clinicians, toxicologists, and policy makers who monitor public health. [1-(5-Fluoropentyl)-1H-indol-3-yl](1-naphthyl)methanone (AM-2201) is an abused synthetic cannabinoid that was initially created as a research tool for investigating the endocannabinoid system. Here we measured the pharmacodynamic effects of AM-2201 in rats, and simultaneously determined plasma pharmacokinetics for the parent drug and its metabolites. Male Sprague-Dawley rats were fitted with surgically implanted temperature transponders and indwelling jugular catheters under pentobarbital anesthesia. One week later, rats received subcutaneous injection of AM-2201 (0.1, 0.3, and 1.0 mg/kg) or its vehicle, and serial blood specimens were withdrawn via catheters. Core temperatures and catalepsy were measured just prior to each blood withdrawal, and plasma was assayed for drug and metabolites using liquid chromatography-tandem mass spectrometry. We found that AM-2201 produced dose-related hypothermia and catalepsy that peaked at 2 hours and lasted up to 8 hours. AM-2201 plasma concentrations rose linearly with increasing dose and ranged from 0.14 to 67.9 µg/l. Concentrations of three metabolites, AM-2201 N-(4-hydroxypentyl) (≤0.17 µg/l), naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) N-(5-hydroxypentyl) (≤1.14 µg/l), and JWH-018 N-pentanoic acid (≤0.88 µg/l) were detectable but much lower. Peak AM-2201, JWH-018 N-(5-hydroxypentyl), and JWH-018 N-pentanoic acid concentrations occurred at 1.3, 2.4, and 6.5 hours, respectively. Concentrations of AM-2201, JWH-018 N-(5-hydroxypentyl), and JWH-018 N-pentanoic acid were negatively correlated with body temperature, but, given the low concentrations of metabolites detected, AM-2201 is likely the major contributor to pharmacodynamic effects under our experimental conditions. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30266766      PMCID: PMC6246978          DOI: 10.1124/jpet.118.250530

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  28 in total

1.  Use of synthetic cannabinoids in patients with psychotic disorders: case series.

Authors:  Andreja Celofiga; Jure Koprivsek; Janez Klavz
Journal:  J Dual Diagn       Date:  2014

2.  Blood synthetic cannabinoid concentrations in cases of suspected impaired driving.

Authors:  Jillian K Yeakel; Barry K Logan
Journal:  J Anal Toxicol       Date:  2013-08-21       Impact factor: 3.367

3.  Synthetic cannabinoids found in "spice" products alter body temperature and cardiovascular parameters in conscious male rats.

Authors:  Charles W Schindler; Benjamin R Gramling; Zuzana Justinova; Eric B Thorndike; Michael H Baumann
Journal:  Drug Alcohol Depend       Date:  2017-08-18       Impact factor: 4.492

4.  Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism.

Authors:  Melanie Hutter; Bjoern Moosmann; Stefan Kneisel; Volker Auwärter
Journal:  J Mass Spectrom       Date:  2013-07       Impact factor: 1.982

5.  Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens.

Authors:  H Ovadia; A Wohlman; R Mechoulam; J Weidenfeld
Journal:  Neuropharmacology       Date:  1995-02       Impact factor: 5.250

6.  Analysis of AM-2201 and metabolites in a drugs and driving case.

Authors:  Albert A Elian; Jeffery Hackett
Journal:  Drug Test Anal       Date:  2013-10-28       Impact factor: 3.345

7.  Simultaneous determination of five naphthoylindole-based synthetic cannabinoids and metabolites and their deposition in human and rat hair.

Authors:  Jihyun Kim; Yuran Park; Meejung Park; Eunmi Kim; Wonkyung Yang; Seungkyung Baeck; Sooyeun Lee; Sangbeom Han
Journal:  J Pharm Biomed Anal       Date:  2014-09-21       Impact factor: 3.935

8.  An accidental fatal intoxication with methoxetamine.

Authors:  Maria Wikström; Gunilla Thelander; Maria Dahlgren; Robert Kronstrand
Journal:  J Anal Toxicol       Date:  2012-10-30       Impact factor: 3.367

9.  Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.

Authors:  Lisa K Brents; Emily E Reichard; Sarah M Zimmerman; Jeffery H Moran; William E Fantegrossi; Paul L Prather
Journal:  PLoS One       Date:  2011-07-06       Impact factor: 3.240

10.  Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice.

Authors:  Timothy W Lefever; Julie A Marusich; Brian F Thomas; Daniel G Barrus; Nicholas C Peiper; Richard C Kevin; Jenny L Wiley
Journal:  Subst Abuse       Date:  2017-04-07
View more
  6 in total

1.  Pharmacokinetics and pharmacodynamics of the synthetic cannabinoid, 5F-MDMB-PICA, in male rats.

Authors:  Alex J Krotulski; Nancy Garibay; Donna Walther; Sara E Walton; Amanda L A Mohr; Barry K Logan; Michael H Baumann
Journal:  Neuropharmacology       Date:  2021-09-20       Impact factor: 5.250

2.  Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats.

Authors:  Michael T Truver; Christina R Smith; Nancy Garibay; Theresa A Kopajtic; Madeleine J Swortwood; Michael H Baumann
Journal:  Neuropharmacology       Date:  2020-06-10       Impact factor: 5.250

3.  Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.

Authors:  Ayat Zagzoog; Asher L Brandt; Tallan Black; Eunhyun D Kim; Riley Burkart; Mikin Patel; Zhiyun Jin; Maria Nikolaeva; Robert B Laprairie
Journal:  Sci Rep       Date:  2021-05-19       Impact factor: 4.379

4.  Pharmacological and Behavioral Effects of the Synthetic Cannabinoid AKB48 in Rats.

Authors:  Sabrine Bilel; Micaela Tirri; Raffaella Arfè; Serena Stopponi; Laura Soverchia; Roberto Ciccocioppo; Paolo Frisoni; Sabina Strano-Rossi; Cristina Miliano; Fabio De-Giorgio; Giovanni Serpelloni; Anna Fantinati; Maria Antonietta De Luca; Margherita Neri; Matteo Marti
Journal:  Front Neurosci       Date:  2019-10-30       Impact factor: 4.677

5.  Genotoxic Properties of Synthetic Cannabinoids on TK6 Human Cells by Flow Cytometry.

Authors:  Monia Lenzi; Veronica Cocchi; Luca Cavazza; Sabrine Bilel; Patrizia Hrelia; Matteo Marti
Journal:  Int J Mol Sci       Date:  2020-02-09       Impact factor: 5.923

6.  In-depth comparison of the metabolic and pharmacokinetic behaviour of the structurally related synthetic cannabinoids AMB-FUBINACA and AMB-CHMICA in rats.

Authors:  David Fabregat-Safont; María Mata-Pesquera; Manuela Barneo-Muñoz; Ferran Martinez-Garcia; Marie Mardal; Anders B Davidsen; Juan V Sancho; Félix Hernández; María Ibáñez
Journal:  Commun Biol       Date:  2022-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.